DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study tests a new drug called purinostat mesylate in 74 adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer that has come back or not responded to treatment). The goal is to see if the drug can shrink tumors and control the disease, while…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo aims to boost CAR T-Cell success in tough lymphomas
Disease control OngoingThis phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a higher stem cell dose beat back lymphoma?
Disease control OngoingThis study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Triple-Target CAR T-Cells take on tough lymphomas
Disease control ENROLLING_BY_INVITATIONThis early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 26, 2026 16:40 UTC
-
Simple test may predict chemo risks for seniors with lymphoma
Knowledge-focused OngoingThis study looks at whether a self-administered geriatric assessment can help predict serious side effects in people aged 60 and older with Non-Hodgkin lymphoma who are starting chemotherapy. The goal is to see if this assessment can identify who is at higher risk for hospitaliza…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC